News Releases All 2024 2023 2022 2021 2020 2019 2023.01.09 Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial 2023.01.05 Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 11 - 12 of 12
2023.01.09 Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial
